Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Control issues

People infected with HIV who control the infection without antiretroviral drug therapy have often served as foot soldiers for science, but now science owes them some answers. If the rare good fortune of being a so-called 'HIV controller' comes with a price—namely, immune activation that raises a person's risks of developing cardiovascular disease, diabetes and other health problems—might antiretroviral medications give these patients' overactive immune systems a much-needed break? Alla Katsnelson investigates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Guaraldi, G. et al. Clin. Infect. Dis. 53, 1120–1126 (2011).

    Article  Google Scholar 

  2. Hunt, P.W. et al. J. Infect. Dis. 197, 126–133 (2008).

    Article  Google Scholar 

  3. Hsue, P.Y. et al. AIDS 23, 1059–1067 (2009).

    Article  CAS  Google Scholar 

  4. Pereyra, F. et al. AIDS 26, 2409–2412 (2012).

    Article  CAS  Google Scholar 

  5. Hatano, H. et al. PLoS Pathog. 9, e1003691 (2013).

    Article  Google Scholar 

  6. Chun, T.-W. et al. J. Infect. Dis. 208, 1443–1447 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Cite this article

Katsnelson, A. Control issues. Nat Med 20, 328–330 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing